Annovis Bio Inc ANVS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2020-01-29 |
| Shares Out. | 34,650,000 |
| Website | annovisbio.com/ ↗ |
| Phone | 13027361777 |
| Employees | 7 |
| Net Income | -$17.6M |
| Total Assets | $16.2M |
| Total Liabilities | $13.1M |
| Equity | $3.1M |
About Annovis Bio Inc
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Annovis Bio Inc is a publicly traded company under the ticker symbol ANVS on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)